Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2006-05-22 14:17:30 UTC |
---|
Update Date | 2022-03-07 02:49:12 UTC |
---|
HMDB ID | HMDB0001984 |
---|
Secondary Accession Numbers | - HMDB0015347
- HMDB01984
- HMDB15347
|
---|
Metabolite Identification |
---|
Common Name | Finasteride |
---|
Description | Finasteride is only found in individuals that have used or taken this drug. Finasteride is an androgen antagonist. It is an orally active testosterone 5-alpha-reductase inhibitor. Finasteride is one of the currently available pharmacologic treatment modalities with proven efficacy for treatment of androgenetic alopecia. The mechanism of action has not been fully determined, but finasteride has shown to decrease scalp DHT concentration to the levels found in hairy scalp, reduce serum DHT, increase hair regrowth, and slow hair loss. Androgenetic alopecia (AGA), or male pattern hair loss, affects approximately 50% of the male population. AGA is an androgen-related condition in genetically predisposed individuals. There is no treatment to completely reverse AGA in advanced stages, but with medical treatment (e.g. finasteride), the progression can be arrested and partly reversed in the majority of patients who have mild to moderate AGA. Finasteride is also used as a surgical alternative for treatment of benign prostatic hyperplasia (PubChem). The mechanism of action of finasteride is based on its preferential inhibition of type II 5alpha-reductase through the formation of a stable complex with the enzyme. Inhibition of type II 5alpha-reductase blocks the peripheral conversion of testosterone to DHT (resulting in significant decreases in serum and tissue DHT concentrations), minimal to moderate increase in serum testosterone concentrations, and substantial increases in prostatic testosterone concentrations. As DHT appears to be the principal androgen responsible for stimulation of prostatic growth, a decrease in DHT concentrations will result in a decrease in prostatic volume (approximately 20-30% after 6-24 months of continued therapy). Finasteride may increase the sensitivity of prostate specific antigen to detect prostate cancer. At present, finasteride remains the only intervention shown in long-term prospective phase III clinical trials to reduce the incidence of prostate cancer (PMID: 18044109 , 17543725 , 17414641 , 17415094 , 17394699 ). |
---|
Structure | [H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C InChI=1S/C23H36N2O2/c1-21(2,3)25-20(27)17-8-7-15-14-6-9-18-23(5,13-11-19(26)24-18)16(14)10-12-22(15,17)4/h11,13-18H,6-10,12H2,1-5H3,(H,24,26)(H,25,27)/t14-,15-,16-,17+,18+,22-,23+/m0/s1 |
---|
Synonyms | Value | Source |
---|
(5alpha,17beta)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide | ChEBI | Finasterida | ChEBI | Finasteridum | ChEBI | Propecia | Kegg | Proscar | Kegg | (5a,17b)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide | Generator | (5Α,17β)-(1,1-dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide | Generator | Chibro-proscar | HMDB | Finastid | HMDB | Finpecia | HMDB | Prostide | HMDB | Chibro proscar | HMDB | Eucoprost | HMDB | Merck brand 1 OF finasteride | HMDB | Merck brand 2 OF finasteride | HMDB | Cahill may roberts brand OF finasteride | HMDB | Lipha brand OF finasteride | HMDB | Merck frosst brand 1 OF finasteride | HMDB | Frosst iberica brand OF finasteride | HMDB | MSD Chibropharm brand OF finasteride | HMDB | Merck sharp and dohme brand 1 OF finasteride | HMDB | Propeshia | HMDB | MSD Brand OF finasteride | HMDB | Merck frosst brand 2 OF finasteride | HMDB | Merck sharp and dhome brand 2 OF finasteride | HMDB |
|
---|
Chemical Formula | C23H36N2O2 |
---|
Average Molecular Weight | 372.5441 |
---|
Monoisotopic Molecular Weight | 372.277678406 |
---|
IUPAC Name | (1S,2R,7R,10S,11S,14S,15S)-N-tert-butyl-2,15-dimethyl-5-oxo-6-azatetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-3-ene-14-carboxamide |
---|
Traditional Name | (1S,2R,7R,10S,11S,14S,15S)-N-tert-butyl-2,15-dimethyl-5-oxo-6-azatetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-3-ene-14-carboxamide |
---|
CAS Registry Number | 98319-26-7 |
---|
SMILES | [H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C |
---|
InChI Identifier | InChI=1S/C23H36N2O2/c1-21(2,3)25-20(27)17-8-7-15-14-6-9-18-23(5,13-11-19(26)24-18)16(14)10-12-22(15,17)4/h11,13-18H,6-10,12H2,1-5H3,(H,24,26)(H,25,27)/t14-,15-,16-,17+,18+,22-,23+/m0/s1 |
---|
InChI Key | DBEPLOCGEIEOCV-WSBQPABSSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Steroids and steroid derivatives |
---|
Sub Class | Androstane steroids |
---|
Direct Parent | Androgens and derivatives |
---|
Alternative Parents | |
---|
Substituents | - 20-hydroxysteroid
- Androgen-skeleton
- 3-hydroxysteroid
- Hydroxysteroid
- 4-azasteroid
- Azasteroid
- Cyclic carboximidic acid
- Carboximidic acid
- Carboximidic acid derivative
- Azacycle
- Organoheterocyclic compound
- Propargyl-type 1,3-dipolar organic compound
- Organic 1,3-dipolar compound
- Organic oxygen compound
- Organopnictogen compound
- Organonitrogen compound
- Organooxygen compound
- Hydrocarbon derivative
- Organic nitrogen compound
- Aliphatic heteropolycyclic compound
|
---|
Molecular Framework | Aliphatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 252 - 254 °C | Not Available | Boiling Point | 576.61 °C. @ 760.00 mm Hg (est) | The Good Scents Company Information System | Water Solubility | 0.002 g/L | Not Available | LogP | 3.03 | HANSCH,C ET AL. (1995) |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross Sections |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Finasteride,1TMS,isomer #1 | CC(C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)[Si](C)(C)C | 3182.3 | Semi standard non polar | 33892256 | Finasteride,1TMS,isomer #1 | CC(C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)[Si](C)(C)C | 3157.4 | Standard non polar | 33892256 | Finasteride,1TMS,isomer #1 | CC(C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)[Si](C)(C)C | 3696.8 | Standard polar | 33892256 | Finasteride,1TMS,isomer #2 | CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4N([Si](C)(C)C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]12C | 3033.8 | Semi standard non polar | 33892256 | Finasteride,1TMS,isomer #2 | CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4N([Si](C)(C)C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]12C | 3159.4 | Standard non polar | 33892256 | Finasteride,1TMS,isomer #2 | CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4N([Si](C)(C)C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]12C | 3511.9 | Standard polar | 33892256 | Finasteride,2TMS,isomer #1 | CC(C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4N([Si](C)(C)C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)[Si](C)(C)C | 3041.4 | Semi standard non polar | 33892256 | Finasteride,2TMS,isomer #1 | CC(C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4N([Si](C)(C)C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)[Si](C)(C)C | 3208.9 | Standard non polar | 33892256 | Finasteride,2TMS,isomer #1 | CC(C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4N([Si](C)(C)C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)[Si](C)(C)C | 3500.7 | Standard polar | 33892256 | Finasteride,1TBDMS,isomer #1 | CC(C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)[Si](C)(C)C(C)(C)C | 3412.9 | Semi standard non polar | 33892256 | Finasteride,1TBDMS,isomer #1 | CC(C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)[Si](C)(C)C(C)(C)C | 3403.5 | Standard non polar | 33892256 | Finasteride,1TBDMS,isomer #1 | CC(C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)[Si](C)(C)C(C)(C)C | 3797.9 | Standard polar | 33892256 | Finasteride,1TBDMS,isomer #2 | CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4N([Si](C)(C)C(C)(C)C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]12C | 3232.4 | Semi standard non polar | 33892256 | Finasteride,1TBDMS,isomer #2 | CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4N([Si](C)(C)C(C)(C)C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]12C | 3394.5 | Standard non polar | 33892256 | Finasteride,1TBDMS,isomer #2 | CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4N([Si](C)(C)C(C)(C)C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]12C | 3617.4 | Standard polar | 33892256 | Finasteride,2TBDMS,isomer #1 | CC(C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4N([Si](C)(C)C(C)(C)C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)[Si](C)(C)C(C)(C)C | 3494.3 | Semi standard non polar | 33892256 | Finasteride,2TBDMS,isomer #1 | CC(C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4N([Si](C)(C)C(C)(C)C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)[Si](C)(C)C(C)(C)C | 3647.9 | Standard non polar | 33892256 | Finasteride,2TBDMS,isomer #1 | CC(C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4N([Si](C)(C)C(C)(C)C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)[Si](C)(C)C(C)(C)C | 3655.1 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Finasteride GC-MS (Non-derivatized) - 70eV, Positive | splash10-0a4i-1579000000-3a73a92e1d34b87c3e4c | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Finasteride GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Finasteride LC-ESI-qTof , Positive-QTOF | splash10-0a4i-5910000000-7dd7b7fbb29b6ae08f4c | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Finasteride LC-ESI-ITFT , positive-QTOF | splash10-0ab9-1319000000-9f18f09bea4e9168f1df | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Finasteride LC-ESI-ITFT , positive-QTOF | splash10-0002-5900000000-3ad6a0d10c51f9892144 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Finasteride LC-ESI-ITFT , positive-QTOF | splash10-0a4i-0119000000-f683db304300c01e907a | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Finasteride LC-ESI-ITFT , positive-QTOF | splash10-0a4i-0129000000-a097bfd2187d4d4c97c6 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Finasteride , positive-QTOF | splash10-00xr-0119000000-43c6646bf19d62255966 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Finasteride , positive-QTOF | splash10-01b9-2539000000-c47506144391db372c4b | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Finasteride LC-ESI-QFT , positive-QTOF | splash10-014i-0900000000-a55cf309ee5a976c5e45 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Finasteride 90V, Positive-QTOF | splash10-0aou-9400000000-e2d92afbb0c688a7c65f | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Finasteride 50V, Positive-QTOF | splash10-0a4i-0936000000-473b441c435f8a167da5 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Finasteride 40V, Positive-QTOF | splash10-05fr-0109000000-a6753fafb9b44a98b5ea | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Finasteride 75V, Positive-QTOF | splash10-0aor-9500000000-2323be14f82809784cbb | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Finasteride 15V, Positive-QTOF | splash10-00di-0009000000-5429921102770ed801ec | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Finasteride 30V, Positive-QTOF | splash10-00di-0009000000-42255449abab8a1efb5b | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Finasteride 30V, Positive-QTOF | splash10-00di-0009000000-5f84c9991fe026c30104 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Finasteride 20V, Positive-QTOF | splash10-00di-0009000000-832f340612f54390180c | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Finasteride 35V, Positive-QTOF | splash10-00di-0009000000-acfb1d6450dbdd3c37ce | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Finasteride 10V, Positive-QTOF | splash10-00di-0009000000-47e745329afb05408179 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Finasteride 55V, Positive-QTOF | splash10-0ab9-0219000000-040ec285d4c909fdf035 | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Finasteride 10V, Positive-QTOF | splash10-00di-0009000000-a6be7718311b4f11aad5 | 2016-08-02 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Finasteride 20V, Positive-QTOF | splash10-0zmi-0439000000-e0a2fad4c18c6da72e1c | 2016-08-02 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Finasteride 40V, Positive-QTOF | splash10-0uej-3790000000-df2f90aa3664e0df8776 | 2016-08-02 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Finasteride 10V, Negative-QTOF | splash10-00di-0009000000-be3980c97e5b8f8767a6 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Finasteride 20V, Negative-QTOF | splash10-00di-3029000000-5489b391a47dec8eb0f1 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Finasteride 40V, Negative-QTOF | splash10-00dl-9131000000-a1b8897126899f67f5fb | 2016-08-03 | Wishart Lab | View Spectrum |
|
---|